Revance Therapeutics Inc (NASDAQ:RVNC)
| 30.46 Delayed Data As of May 26 |  -0.35 / -1.14%Today’s Change | 11.27 Today|||52-Week Range 37.98 | +65.01% Year-to-Date |
Five Year Financial Summary
| All Currency in US Dollars | 4 Year Trend | |||||
|---|---|---|---|---|---|---|
2015 | 2016 | 2017 | 2018 | |||
| Operating Activities | Net Income / Starting Line | -73.5M | -89.3M | -120.6M | -142.6M | |
| Depreciation | 2.0M | 1.4M | 1.5M | 1.7M | ||
| Total Other Cash Flow | 13.3M | 25.2M | 17.3M | 13.9M | ||
| Funds From Operations | -58.2M | -62.6M | -101.8M | -127.0M | ||
| Funds From/For Other Operating Expenses | -2.5M | -2.8M | -6.4M | -22.7M | ||
| Net Cash Flow - Operating Activities | -55.7M | -59.8M | -95.3M | -104.2M | ||
| Investing | Increase In Investments | -54.1M | -280.7M | -36.0M | -314.9M | |
| Decrease In Investments | 1.1M | 208.7M | 157.4M | 213.4M | ||
| Capital Expenditures | -3.3M | -1.7M | -2.5M | -7.0M | ||
| Fixed Asset Disposal | -- | 2.0K | 0.00 | 1.5M | ||
| Net Assets From Acquisitions | 0.00 | -1.8M | -100.0K | -100.0K | ||
| Net Cash Flow Investing | -56.3M | -75.5M | 118.8M | -107.0M | ||
| Financing | Short Term Borrowings | -- | -- | -- | 0.00 | -- |
| Long Term Borrowings | 9.8M | 0.00 | 0.00 | 0.00 | ||
| Long Term Debt Reduction | -5.3M | -3.5M | -3.6M | -932.0K | ||
| Net Proceeds Stock Sale | 139.0M | 1.4M | 200.2M | 4.9M | ||
| Common Preferred Redeemed | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Common Dividends | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Cash Dividends Paid - Total | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Other Sources - Financing | -- | -- | -- | 0.00 | -- | |
| Other Uses - Financing | 993.0K | 507.0K | 573.0K | 2.2M | ||
| Net Cash Flow - Financing | 142.6M | -2.6M | 195.9M | 1.8M | ||
| Exchange Rate | Effect of Exchange Rate on Cash | -- | -- | -- | -- | -- |
| Net Change In Cash | 30.6M | -138.0M | 219.4M | -209.5M | ||
